TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on Thursday, May 29, 2025 to discuss the acceleration phase of its strategy and portfolio priorities. The event will take place in New York, N.Y. Presentations will begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time.
Richard Francis, Teva's President and CEO, along with other members of the executive management team will discuss an update on the strategy and key priorities focusing on growth and innovation.
Due to limited capacity, in-person attendance is by invitation only. Analysts and institutional investors will be invited to pre-register and attend through an invite that will is distributed separately.
For questions regarding the event, please contact Teva's Investor Relations team at TevaIR@Tevapharm.com.
A live webcast of the event and presentation materials will be available on Teva's Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24 hours after the end of the live discussion.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients’ needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors” and "Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
-
顺峰宝宝深度参与第五届上海交大皮肤病研究所论坛 产学研协同推动皮肤健康发展近日,第五届上海交大皮肤病研究所论坛在上海成功举办。作为皮肤科学界的年度盛事,论坛吸引了国内外皮肤科领域顶尖专家齐聚一堂,围绕炎症免疫、遗传儿童皮肤病、皮肤2025-05-08
-
醒狮入魂,山海可期,长城灵魂S2000佛山试驾品鉴会震撼启幕2025年4月19日—20日,佛山顺德运动机车协会引擎轰鸣,鼓点激昂。长城灵魂摩托灵魂所至·驾趣山海全国试驾品鉴会第二站在此震撼启幕。作为中国高端摩托车领域的破2025-05-08
-
醒狮入魂,山海可期,长城灵魂S2000佛山试驾品鉴会震撼启幕2025年4月19日—20日,佛山顺德运动机车协会引擎轰鸣,鼓点激昂。长城灵魂摩托灵魂所至·驾趣山海全国试驾品鉴会第二站在此震撼启幕。作为中国高端摩托车领域的破2025-05-08
-
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~4For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our2025-05-08
-
EASL重磅!SCG101一期临床展现乙肝清除、肿瘤消退双重功效新加坡2025年5月8日 /美通社/ -- 2025年5月8日,在荷兰阿姆斯特丹2025年欧洲肝病年会(EASL2025)上,星汉德生物HBV特异性TCR-T细胞疗法 - SCG101再度登上最新突破(Lat2025-05-08